Andere Sprachen Pacira BioSciences, Inc.

Aktien

A1H68T

US6951271005

PCRX

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:05:03 25.04.2024			% 5 Tage	% 1. Jan.
25.5 ^USD	-1.56%		-2.45%	-24.54%

13.03.	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
13.03.	Pacira BioSciences gibt bekannt, dass die US FDA dem Therapiekandidaten gegen Kniearthrose den RMAT-Status zuerkannt hat	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Los bancos occidentales advierten de los riesgos del plan de la UE para usar los activos rusos	22.03.
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20.03.
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	13.03.
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	13.03.
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13.03.
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13.03.
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	13.03.
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	08.03.
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference	06.03.
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	29.02.
Pacira: Q4 Earnings Snapshot	29.02.
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29.02.
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024	29.02.
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	29.02.
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	29.02.
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	29.02.
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results	29.02.
North American Morning Briefing : Fed's Preferred -2-	29.02.
Pacira to Report 2023 Financial Results on Thursday February 29, 2024	22.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pacira BioSciences, Inc.

Aktien

A1H68T

US6951271005

PCRX

Andere Sprachen

Filter